Trial Information
Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer
Inclusion Criteria:
- Patients with (residual) oligometastatic CRC: ≤ 5 mets
- Primary tumor treated with curative intention (surgery, radiotherapy,
chemoradiotherapy)
- Functional liver volume > 1000cc if livermets, lung DLCO > 30% if lungmets.
- No Child B or C liver cirrhosis
- No contra-indications for radiation of all metastatic CRC (= no violation of
constraints of organs at risk (OAR))
- No mets from another carcinoma
- Age > 18 years
- WHO-PS ≤ 2
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Metabolic complete remission rate
Outcome Time Frame:
Three months
Safety Issue:
No
Principal Investigator
Mark De Ridder, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
RCT501
NCT ID:
NCT00807313
Start Date:
December 2008
Completion Date:
July 2011
Related Keywords:
- Colon Cancer
- Rectal Cancer
- Colorectal Cancer
- Oligometastatic disease
- Colorectal cancer
- Stereotactic body radiotherapy
- Tomotherapy
- Metabolic response
- Stage IV
- Colonic Neoplasms
- Rectal Neoplasms
- Colorectal Neoplasms